Testagen
Also known as: Peptídeo testicular
Molecular Identifiers
Molecular Formula
C17H29N5O9
CAS Number
473578-47-1
PubChem CID
123863700Molecular Weight
447.44 Da
Overview
Bioregulatory tetrapeptide developed by Professor Khavinson's group. Researched for its ability to regulate testicular function and modulate gene expression in Leydig and Sertoli cells.
Testagen is proposed as a peptide bioregulator of testicular function, acting on Leydig and Sertoli cells through epigenetic modulation and regulation of gene expression. Reported effects include support for endogenous steroidogenesis and spermatogenesis, in short cyclic protocols. Unlike classical hormonal therapies, it does not replace hormones: the proposed mechanism is to restore the tissue's regulatory function.
Outside of Russia, Testagen has no regulatory approval or recognized clinical indication. It is dispensed by compounding pharmacies as off-label use in 10 to 20 day cycles, repeated 2 to 4 times per year, often combined with other Khavinson peptides. Available scientific evidence is concentrated in Russian publications from the St. Petersburg Institute of Bioregulation and Gerontology, with few independent human clinical trials.
Within the Khavinson family, Testagen occupies the testicular/HPG niche, in parallel with Prostamax (prostate) on the male urogenital axis: each one is distinguished less by overall mechanism and more by proposed target tissue, with Testagen focused on Leydig and Sertoli cells and on supporting endogenous steroidogenesis. All of this comparative literature is largely Russian and preclinical.
KEDG Lys-Glu-Asp-Gly Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Hormonal Regulation
Mechanism of Action
- Regulation of testicular function via epigenetic modulation
- Modulation of gene expression in Leydig cells
- Influence on endogenous testosterone synthesis
- Interaction with DNA in the regulation of testis-specific genes
- Bioregulatory effect on spermatogenesis
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 2 capsules orally (0.2-0.275 g per capsule, containing AKS-S peptide complex) |
| Frequency | 1-2 times daily, before meals |
| Timing | Before meals |
| Duration | 1 month per cycle, repeat the course every 3-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Testagen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Testagen.
Related Peptides
Argipressin
5-20 IU or 1-4 mcg/kg · As clinically needed
Cetrorelix
0.25-3 mg per injection · Once daily (0.25 mg) or single dose (3 mg)
Gonadorelin
100-200 mcg per injection · 2-3 times per week
HCG
250-500 IU per injection · 2-3 times per week
Kisspeptin-10
1-10 mcg per injection · Per research protocol
α-MSH
0.5-2 mg per injection · Once daily or every other day